Article Text

Download PDFPDF
Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY)
  1. Giovanni Scambia1,2,
  2. Camilla Nero1,2,
  3. Stefano Uccella3,
  4. Enrico Vizza4,
  5. Fabio Ghezzi5,
  6. Francesco Cosentino6,
  7. Vito Chiantera7,8 and
  8. Anna Fagotti1,2
  1. 1 Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
  2. 2 Università Cattolica del Sacro Cuore, Roma, Italy
  3. 3 Nuovo Ospedale degli Infermi Dipartimento di Oncologia di Biella, Ponderano, Italy
  4. 4 Regina Elena Institute, Roma, Italy
  5. 5 Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy
  6. 6 Catholic University of the Sacred Heart Campobasso Campus, Campobasso, Italy
  7. 7 Department of Gynecologic Oncology, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy
  8. 8 Department of Gynecologic Oncology, University of Palermo, Palermo, Italy
  1. Correspondence to ScambiaGiovanni, Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma 00168, Italy; giovanni.scambia{at}


Background Systematic para-aortic and bilateral pelvic lymphadenectomy is included in the standard comprehensive surgical staging in presumed early epithelial ovarian cancer. No prospective randomized evidence suggests it has potential therapeutic value, and related morbidity is not negligible.

Primary Objective(s) To assess sensitivity, safety, and feasibility of the sentinel lymph node technique in identifying the presence of lymph node metastases in patients with early stage epithelial ovarian cancer.

Study Hypothesis Sentinel lymph node detection with indocyanine green can accurately predict nodal status in a cohort of women with early stage epithelial ovarian cancer.

Trial Design The SELLY trial is a prospective phase II interventional multicenter study.

Major Inclusion/Exclusion Criteria Inclusion criteria: Eastern Cooperative Oncology Group 0–1, apparent International Federation of Gynecology and Obstetrics (FIGO) stage I-II, histologically proven epithelial ovarian cancer.

Exclusion criteria: evidence of carcinomatosis, mucinous only at definitive histology.

Endpoint(s) Primary endpoint is sensitivity (true positive rate). Secondary endpoints include safety (complications rate of the procedure) and feasibility.

Sample Size Assuming a sensitivity of 98.5% in predicting positive sentinel lymph nodes at histology, a pathological lymph node prevalence of 14.2%, a precision of estimate (ie, the maximum marginal error) d=5%, and a type I error α=0.05, a sample size of 160 patients is needed to test the general hypothesis (ie, to answer whether sentinel lymph nodes identified with indocyanine green can accurately predict nodal status at histology of patients with apparently early epithelial ovarian cancer). Assuming a drop-out rate of 10%, a total of 176 patients will be enrolled in the study.

Estimated Dates for Completing Accrual and Presenting Results The accrual should be completed by December 2020 and results should be presented by March 2021.

Trial Registration The trial is registered at (NCT03563781).

  • early ovarian cancer
  • indocyanine green (ICG)
  • laparoscopy
  • lymphadenectomy
  • minimally-invasive surgery
  • sentinel node

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SU, CN did the study design, patient recruitment, data analysis and interpretation, statistical analysis, and wrote the report. AF and GS supervised the whole process. SU, CN, EV, FG, FC, AF and GS participated in patient recruitment. SU and CN contributed to collection and organization of the data. All authors approved the final report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Commissioned; externally peer reviewed.